全文获取类型
收费全文 | 15753篇 |
免费 | 1153篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 279篇 |
儿科学 | 426篇 |
妇产科学 | 402篇 |
基础医学 | 2409篇 |
口腔科学 | 436篇 |
临床医学 | 1621篇 |
内科学 | 3003篇 |
皮肤病学 | 286篇 |
神经病学 | 1409篇 |
特种医学 | 637篇 |
外国民族医学 | 1篇 |
外科学 | 2165篇 |
综合类 | 197篇 |
一般理论 | 50篇 |
预防医学 | 1322篇 |
眼科学 | 410篇 |
药学 | 1066篇 |
中国医学 | 16篇 |
肿瘤学 | 829篇 |
出版年
2023年 | 53篇 |
2021年 | 215篇 |
2020年 | 129篇 |
2019年 | 242篇 |
2018年 | 301篇 |
2017年 | 231篇 |
2016年 | 259篇 |
2015年 | 301篇 |
2014年 | 395篇 |
2013年 | 742篇 |
2012年 | 870篇 |
2011年 | 1052篇 |
2010年 | 569篇 |
2009年 | 487篇 |
2008年 | 892篇 |
2007年 | 943篇 |
2006年 | 872篇 |
2005年 | 874篇 |
2004年 | 926篇 |
2003年 | 840篇 |
2002年 | 892篇 |
2001年 | 149篇 |
2000年 | 113篇 |
1999年 | 152篇 |
1998年 | 199篇 |
1997年 | 150篇 |
1996年 | 132篇 |
1995年 | 154篇 |
1994年 | 149篇 |
1993年 | 129篇 |
1992年 | 92篇 |
1991年 | 86篇 |
1990年 | 80篇 |
1989年 | 90篇 |
1988年 | 82篇 |
1987年 | 90篇 |
1986年 | 77篇 |
1985年 | 96篇 |
1984年 | 108篇 |
1983年 | 86篇 |
1982年 | 154篇 |
1981年 | 126篇 |
1980年 | 127篇 |
1979年 | 71篇 |
1978年 | 82篇 |
1977年 | 74篇 |
1976年 | 68篇 |
1974年 | 72篇 |
1973年 | 57篇 |
1963年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Hyperhidrosis can seriously impair patients’ quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 ± 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (–18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment‐related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged. 相似文献
3.
Aneesh Dhorepatil Somedeb Ball Raktim K. Ghosh Meera Kondapaneni Carl J. Lavie 《The American journal of medicine》2019,132(3):312-324
Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic diseases and malignancies. The interleukin family has been critically associated with progression of atherosclerosis, insulin resistance, and various malignancies. Given the advent of pharmacologic interleukin-1 (IL-1) inhibition, this pathway can potentially be targeted to improve outcomes. In the recently concluded Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial, investigators looked at the potential role of IL-1 (especially IL-1β) inhibition in halting the progression of atherosclerosis. In the subset analysis of the data from this trial, IL-1β inhibition with canakinumab was found to have beneficial effects in other cardiometabolic diseases characterized by inflammation, like diabetes, stroke, and chronic kidney disease, and also in patients with lung cancer. In this article, we will try to review the current literature on the role of canakinumab in the treatment of cardiometabolic diseases and malignancies. 相似文献
4.
Marco Giuseppe Del Buono Ross Arena Barry A. Borlaug Salvatore Carbone Justin M. Canada Danielle L. Kirkman Ryan Garten Paula Rodriguez-Miguelez Marco Guazzi Carl J. Lavie Antonio Abbate 《Journal of the American College of Cardiology》2019,73(17):2209-2225
Exercise intolerance is the cardinal symptom of heart failure (HF) and is of crucial relevance, because it is associated with a poor quality of life and increased mortality. While impaired cardiac reserve is considered to be central in HF, reduced exercise and functional capacity are the result of key patient characteristics and multisystem dysfunction, including aging, impaired pulmonary reserve, as well as peripheral and respiratory skeletal muscle dysfunction. We herein review the different modalities to quantify exercise intolerance, the pathophysiology of HF, and comorbid conditions as they lead to reductions in exercise and functional capacity, highlighting the fact that distinct causes may coexist and variably contribute to exercise intolerance in patients with HF. 相似文献
5.
6.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.7.
8.
Ryan S. Falck Robin P. Shook Gregory A. Hand Carl J. Lavie Steven N. Blair 《Postgraduate medicine》2015,127(3):282-288
Extreme weight changes, or changes in weight greater than 10 kg within a 2-year period, can be caused by numerous factors that are much different than typical weight fluctuations. This paper uses two interesting cases of extreme weight change (a female who experienced extreme weight gain and a male who experienced extreme weight loss) from participants in the Energy Balance Study to illustrate the physiological and psychosocial variables associated with the weight change over a 15-month period, including rigorous assessments of energy intake, physical activity (PA) and energy expenditure, and body composition. In addition, we provide a brief review of the literature regarding the relationship between energy balance (EB) and weight change, as well as insight into proper weight management strategies. The case studies presented here are then placed in the context of the literature regarding EB and weight change. This report further supports previous research on the importance of regular doses of PA for weight maintenance, and that even higher volumes of PA are necessary for weight loss. Practitioners should emphasize the importance of PA to their patients and take steps to monitor their patients’ involvement in PA. 相似文献
9.
10.
Carl M. Gay C. Allison Stewart Elizabeth M. Park Lixia Diao Sarah M. Groves Simon Heeke Barzin Y. Nabet Junya Fujimoto Luisa M. Solis Wei Lu Yuanxin Xi Robert J. Cardnell Qi Wang Giulia Fabbri Kasey R. Cargill Natalie I. Vokes Kavya Ramkumar Bingnan Zhang Lauren Averett Byers 《Cancer cell》2021,39(3):346-360.e7